Why is a GIP/GLP-1 drug like brenipatide being studied for depression and bipolar disorder?

The development program is exploring whether a drug acting on metabolic hormone receptors can also improve clinically important psychiatric outcomes. The strongest public evidence for that interest is the trial design itself: RENEW-MDD-1 compares brenipatide plus standard care with placebo plus standard care to test whether major depressive symptoms return later. RENEW-Bipolar-1 separately tests whether it delays worsening or relapse alongside existing care. Those are prevention and maintenance questions, not simply whether a dose produces an immediate improvement in mood.[1][2]

The mechanism remains a hypothesis to test against patient outcomes. The existence of GIP/GLP-1 signaling does not prove that brenipatide directly treats depression, corrects a chemical imbalance or acts like a conventional mood stabilizer. Even a positive trial would need careful interpretation of weight changes, metabolic effects, background medications and adverse events. Depression and bipolar disorder also require separate evidence; success in one cannot be presumed in the other. These adjunctive trials do not support stopping an antidepressant or bipolar medication to substitute brenipatide.[1][2][3]